Oblenio Bio
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $62M
Investors
- 4
About Oblenio Bio
Founded in 2024 and headquartered in Lexington, US, Oblenio Bio, Inc. is dedicated to the advancement of therapies for autoimmune diseases. Oblenio Bio specializes in the development of innovative therapies targeting refractory autoimmune diseases, with its core product being the LBL-051 T-cell engager. This tri-specific antibody is engineered to target BCMA, CD19, and CD3, facilitating the safe and effective depletion of pathological B-cells and plasma cells. Designed for patients suffering from severe autoimmune conditions, LBL-051 aims to achieve long-term drug-free remission, offering a potentially groundbreaking approach to treatment. The company is focused on advancing LBL-051's clinical development, with applications across a broad spectrum of autoimmune diseases, including but not limited to rheumatoid arthritis and systemic lupus erythematosus.Oblenio Bio’s revenue generation strategy primarily revolves around the clinical development and commercialization of its flagship product, LBL-051. The company engages in partnerships with healthcare providers, research institutions, and pharmaceutical companies to facilitate the development and distribution of its therapies. These collaborations involve a combination of licensing agreements and direct sales to hospitals and clinics managing autoimmune disease treatments. Transactions are structured around milestone payments, contingent upon achieving specific development goals, along with royalties on sales post-commercialization.In June 2026, Oblenio Bio, Inc. The company plans to design and launch new products targeting additional autoimmune conditions, expanding its market reach into North America and Europe by 2028.
Who invested in Oblenio Bio
4 investors across 1 round
See all investors in Oblenio Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jun 25, 2026
Amount
$62M
Investors
Questions about Oblenio Bio
Who invested in Oblenio Bio?
Oblenio Bio has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oblenio Bio raised?
Oblenio Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Oblenio Bio last raise money?
Oblenio Bio's most recent round on record is a Series B, in Jun 2026.
What does Oblenio Bio do?
Founded in 2024 and headquartered in Lexington, US, Oblenio Bio, Inc.
Where is Oblenio Bio headquartered?
Oblenio Bio is headquartered in Lexington, US.
Which VCs invest in companies like Oblenio Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Oblenio Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Oblenio Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.